Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
STRONTIUM CHLORIDE SR-89 FOR TREATING PAIN FROM METASTATIC BONE-DISEASE
Autore:
NIGHTENGALE B; BRUNE M; BLIZZARD SP; ASHLEYJOHNSON M; SLAN S;
Indirizzi:
UNIV OKLAHOMA,HLTH SCI CTR,COLL PHARM,POB 26901 OKLAHOMA CITY OK 73190 H LEE MOFFIT CANC CTR & RES INST,DEPT PHARM TAMPA FL 00000 VET AFFAIRS MED CTR,PRIME CLIN COLUMBIA SC 00000 REVCO PHARM GREENVILLE SC 00000 FARM FRESH SUPERMARKET PHARM HAMPTON VA 00000
Titolo Testata:
American journal of health-system pharmacy
fascicolo: 20, volume: 52, anno: 1995,
pagine: 2189 - 2195
SICI:
1079-2082(1995)52:20<2189:SCSFTP>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
HALF-BODY IRRADIATION; THERAPY ONCOLOGY GROUP; SR-89 THERAPY; BREAST-CANCER; PROSTATIC-CARCINOMA; RADIATION-THERAPY; SKELETAL METASTASES; OSSEOUS METASTASES; RANDOMIZED TRIAL; SOLID TUMORS;
Keywords:
DOSAGE SCHEDULES; DRUG ADMINISTRATION RATE; INJECTIONS; MECHANISM OF ACTION; NEOPLASM METASTASIS; PAIN; RADIOPHARMACEUTICALS; SITE OF ACTION; STRONTIUM CHLORIDE SR 89; TOXICITY; TOXICITY, ENVIRONMENTAL;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
87
Recensione:
Indirizzi per estratti:
Citazione:
B. Nightengale et al., "STRONTIUM CHLORIDE SR-89 FOR TREATING PAIN FROM METASTATIC BONE-DISEASE", American journal of health-system pharmacy, 52(20), 1995, pp. 2189-2195

Abstract

The role of strontium chloride Sr 89 in the palliative treatment of pain associated with metastatic bone disease is reviewed. Conventional therapies to relieve metastatic bone pain include nonopioid and opioidanalgesics, hormonal therapy, external-beam irradiation, and chemotherapy. Limitations in the long-term safety and effectiveness of these treatments have increased interest in using systemic radioactive isotopes for palliation of pain. Strontium chloride Sr 89 is a relatively new bone-seeking radiopharmaceutical that has FDA-approved labeling for use in relieving pain associated with skeletal metastases. An analogueof calcium, strontium chloride Sr 89 is rapidly cleared from the blood after i.v. injection. The agent selectively irradiates metastatic sites while generally sparing normal soft-bone tissue. In clinical studies, a majority of patients with prostate or breast cancer obtained substantial relief from bone pain after receiving strontium chloride Sr 89 alone or in combination with external-beam irradiation. Adverse effects tend to be mild, but patients should be monitored for possible hematologic toxicity. Patients should discontinue any calcium-containing products before receiving the agent. The typical dose is 4 mCi (148 MBq) administered by slow i.v. push over one to two minutes; doses can be repeated at three-month intervals. Pain relief usually begins in 10-20 days and lasts up to six months. Radiation safety measures are necessary in handling strontium chloride Sr 89 and the wastes of patients. Strontium chloride Sr 89 is costly, but preliminary analysis indicates that it may reduce management expenditures overall. Strontium chloride Sr 89, used either alone or in combination with external-beam irradiation, is generally effective in relieving metastatic bone pain and can reduce or eliminate the need for analgesics.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 12:26:06